Tyrosine kinase inhibitors are currently front-line therapy for chronic myelogenous leukemia (CML), but relapse from drug resistance remains an important problem. Because BCR-ABL mutations arise in the setting of drug resistance, we sought to identify potential neoantigens derived from mutated BCR-ABL that could be targeted for the treatment of this immuneresponsive malignancy. We identified polyfunctional E255K-specific CD8+ T cells from two imatinib-resistant HLA-A3+ CML patients arising in the setting of effective anti-CML response to further therapy. Our studies demonstrate that leukemia-driven genetic alterations can be targeted by the immune system in association with a clinical response. Our studies support the approach of immunizing relapsed CML patients against newly acquired tumor neoantigens as a promising anti-leukemia treatment strategy.
INTRODUCTION
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder whose pathognomonic feature is translocation between chromosomes 9 and 22 to form the fusion protein BCR-ABL.
This gene fusion results in constitutive activation of the ABL kinase whose oncogenic properties have been well-described (1, 2) . For decades, enduring curative therapy for young patients with CML has been achieved with allotransplantation (allo-HSCT) (although at significant risk of toxicities) and these results have provided clear demonstration of the potency of donor immunity in eradicating leukemia through graft-versus-leukemia (GvL) effects (3) . The well-tolerated BCR-ABL targeting tyrosine kinase inhibitor (TKI) imatinib, however, has emerged as front-line therapy, since its FDA approval in 2001 (4) . More potent second-generation TKIs, dasatinib and nilotinib, have also been developed and approved for treatment of CML with prior imatinib exposure (5-6). All three TKIs efficiently inhibit the catalytic activity of BCR-ABL by binding to the ATP-binding pocket of the ABL kinase domain (7) .
While imatinib effectively controls CML with relatively minor toxicity, relapse and drug resistance remain as important problems, with annual progression rates of 3.3-7.5% during the first three years of treatment (8, 9) . The most common mechanism of drug resistance is the emergence of various BCR-ABL kinase domain mutations (10) , with detection of BCR-ABL 6 (11%), E255 (10.5%), T315 (13.5%), M351 (10%), F359 (6.5%) and H396 (5%) (10, 14, 15) .
Resistance to second-generation TKIs has been likewise observed, with each drug generating its own spectrum of BCR-ABL mutations (16) (17) (18) .
Therapeutic alternatives that complement the potent cytolytic effects of TKIs and address drug resistance would substantively advance the treatment of patients with CML. In particular, an immunotherapeutic approach is promising for CML, due to its exquisite sensitivity to immune modulation (19) . BCR-ABL has been suggested as an ideal immunologic target since, it is essential for leukemogenesis and its expression is specific to CML. However, chronic expression of this cancer-driving leukemia protein may result in selective host deletion of high avidity T cells directed against BCR-ABL expressing cells, as has been described for another CML-associated antigen PR-1 (20) , or in reduced anti-tumor functionality. Consistent with this idea, T cells with specificity for BCR-ABL have been detected in CML patients, but they demonstrate poor cytolytic activity (21) . Conversely, as tumors evolve, such as with drug resistance, newly-acquired genetic alterations may generate novel peptides that can stimulate new CTL clones, although immunosuppression exerted by leukemia cells may prevent these from controlling expansion of leukemia cells in vivo (22, 23) . Fortunately, however, new potent adjuvants and checkpoint blockade inhibitors are now available that have the potential to circumvent these obstacles and will likely be incorporated in future immunotherapies (24) (25) (26) (27) .
Herein, we present a strategy to evaluate the immunogenicity of peptides generated from mutated BCR-ABL. This analysis is facilitated by the increasing accuracy of algorithms that predict binding capacity of peptides to a wide range of HLA alleles (28) . We detected that T cell responses against processed mutated BCR-ABL peptides develop in association with tumor 
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regression following allo-HSCT or second line TKIs. While the concept of tumor neoantigens as a target for immunotherapeutics has been long studied (29) , our studies are the first to demonstrate that mutations that develop in the setting of drug resistance can be an abundant source of tumor-specific antigens. Our results provide a proof-of-concept for a systematic approach to discover immunogenic tumor antigens arising from evolving genetic alterations, with potential for developing novel immunotherapies.
Research. 
Detection of BCR-ABL mutations
Mutations in BCR-ABL were detected by polony assay, described previously (30) , or by routine molecular diagnostics at the Brigham and Women's Hospital, Boston. In the latter process, total RNA was isolated from unfractionated peripheral blood or bone marrow cells, and reversetranscribed with the ABL primer downstream of the kinase domain and PCR-amplified with primers across the BCR-ABL junction. The resulting PCR product was purified and analyzed by Sanger sequencing.
Prediction of peptide binding to HLA alleles.
To discover peptide targets, MHC-binding affinity was predicted across all possible 9mer and 10mer peptides encoded by ABL mutations by using MHC-peptide binding prediction algorithms which have been independently verified as highly accurate (28, 31 (32) . Alternatively, we used the IEDB SMM (IEDB) algorithm, which met the criterion for high accuracy for HLA-A*02:01, *03:01, *11:01, B*07:02, *08:01, and *15:01 (28) . An IC 50 < 50 nM was considered a predicted strong binder, an IC 50 >50 and <500 nM was considered an intermediate binder, and IC 50 between 500 and 1000 nM was considered a weak binder.
Experimental binding of peptides
Experimental confirmation of peptide-MHC prediction of a subset of peptides was performed using a competitive MHC allele binding assay to test binding to several common HLA alleles (A*02:01, A*03:01, A*11:01, B*07:02, B*15:01). This assay measures the ability of peptide ligands to inhibit the binding of a high affinity radiolabeled peptide to purified MHC molecules, and has been described in detail elsewhere (33) . Briefly, purified MHC molecules, test peptides, and a radiolabeled probe peptide were incubated at room temperature in the presence of human β2-microglobulin and a cocktail of protease inhibitors. After a two-day incubation, binding of the radiolabeled peptide to the corresponding MHC class I molecule was determined by capturing MHC/peptide complexes on W6/32 antibody (anti-HLA A, B, and C) or B123.2 (anti-HLA B, C and some A) coated plates, and measuring bound cpm using a microscintillation counter. For competition assays, the concentration of peptide yielding 50% inhibition of radiolabeled peptide binding was calculated. Peptides were typically tested at 6 different concentrations covering a 100,000-fold dose range, and in 3 or more independent assays. Under the conditions utilized, where [ 
Sources of antigen
Peptides were synthesized to >95% purity (confirmed by high performance liquid chromatography, New England Peptide; Gardner MA). Peptides were reconstituted in DMSO (10 mg/ml) and stored at -20°C until use. A minigene comprised of a sequence of 227bp encompassing the E255K mutation was PCR-cloned into the HindIII and EcoRI restriction enzyme sites of the expression vector pcDNA3.1 using the following primers: 5'-primer:
ATAGAATTCTGCAGTCAATGGTGATGGTGATGATGTCACTCTTCCACCTCCATGGT.
To express the E255K mutation in target cells of T cell assays, 10 µg of the minigene plasmid 
Generation of antigen presenting cells (APCs)
Autologous dendritic cells (DCs) were generated from immunomagnetically-isolated CD14+ buffer in the presence of 120 ng/ml GM-CSF (Genzyme, Cambridge, MA) and 70 ng/ml IL-4 (R&D Systems, Minneapolis, MN). On days three and five, additional GM-CSF and IL-4 were added. On day six, cells were matured for 48 hours with 10 ng/ml TNF-α (Genzyme, Cambridge, MA) and 1 μg/ml prostaglandin E2 (Sigma-Aldrich, St. Louis MO). CD40-B cells were generated from PBMC by activation on CD40L-expressing irradiated feeder cells in the presence of IL-4 (R&D Systems) and cyclosporin A (Novartis, Basel, Switzerland) as described (36) . The MHC class I-deficient immortalized B lymphoblastoid cell line 721.221 was retrovirally infected with a plasmid encoding the full-length A*03:01 (designated B721.221/A3 cells), and maintained in DMEM supplemented with 10% FCS, 2mM L-glutamine, antibiotics (Invitrogen), and 500 ng/mL of G418 (Cellgro).
Generation of antigen-specific T cells from normal volunteer and patient PBMC
To generate E255K-reactive T cells from a healthy adult volunteer, PBMC from an HLA-A3+ individual was cultured in 24-well plates (10x10 6 cells/well) in complete medium supplemented with 10% human AB serum and 10 ng/mL IL-7, together with autologous DCs (at 1:100 ratio) that were pulsed for 3 hours with 10 μM peptide. On day 6, CD8+ T cells were immunomagnetically isolated from PBMC (CD8+ Microbeads, Miltenyi, Auburn CA). CD8+ T cells were co-cultured with irradiated B721.221/A3 cells (3200 Gy) pulsed with 10μM peptide at a ratio of 10:1 in the presence of IL-7 (10 ng/mL) on days 7, 14, 21, and 28, and T cell specificity was tested one week after last stimulation. E255K-specific T cells were similarly A priority in the field of immunotherapy is the identification of targetable tumor-specific epitopes that do not elicit cross-reactivity to normal tissue. We therefore examined whether the predicted mutated peptides had increased binding affinity compared to respective parental peptides. As shown in Figure 1B were predicted to bind with IC 50 < 1000 nM, with 60 peptide-allele combinations (Supplemental Figure 1) . Twenty-three (38%) had at least two-fold greater affinity for HLA binding than the wild-type parental peptide. Overall, 46 peptide-allele combinations were common to both the NetMHC and IEDB servers. These analyses demonstrate that mutated BCR-ABL has the potential to generate neopeptides that can bind to common HLA alleles.
Imatinib-resistant CML patients can potentially express immunogenic mutated BCR-ABL epitopes
To establish the frequency that immunogenic peptides arising from mutated BCR-ABL can potentially be generated from CML patients, we analyzed nine imatinib-resistant CML patients, whose HLA typing and BCR-ABL mutation status were known. All patients had been exposed to imatinib for a median of 6 months (range 1-33) before developing drug resistance (Table 1 ).
All leukemia samples harbored a median of 1 BCR-ABL mutation (range 1-3). In total, 20 distinct HLA-A and -B alleles were represented among the 9 patients, and 8 distinct mutations were detected, 5 of which were unique to particular patients.. The three most common HLA alleles were A1, A2 and B7, represented in 4, 5 and 4 patients, respectively.
As shown in Figure 2 
To validate the HLA binding predictions, we synthesized fifty-five 9-and 10-mers derived from mutated and wild-type BCR-ABL and determined their binding capacity (IC50 nM) using a wellestablished competitive MHC binding assay (33) . We focused on peptides predicted to have high binding affinity (IC 50 < than 100 nM) by NetMHC, for which IEDB binding predictions were also available.
We observed that experimental binding was highly related to the extent of concordance between NetMHC and IEDB prediction results. As shown in Figure 3 We subsequently focused our attention on peptides E255K-A and E255K-B. Each was predicted to strongly bind to HLA-A*03:01 with at least ten-fold greater affinity than their parental peptides by both NetMHC and IEDB. Both were experimentally confirmed to bind HLA-A3 with high affinity (IC 50 scores of 208 nM and 17 nM, respectively, Table 2 ). In addition, E255K-B also bound other HLA-A3 superfamily members HLA-A*11:01, HLA-A*30:01, HLA-A*31:01 and HLA-A*68:01 with high to moderate affinity (IC 50 : 39-603 nM).
Mutated BCR-ABL peptide E255K-B is immunogenic
T cell lines were generated against the E255K-B peptide but not E255K-A from PBMC of a normal HLA-A3+ volunteer, following four rounds of weekly stimulation of T cells against mutated peptide-pulsed autologous APCs. To assess the specificity of T cell response, we generated HLA-A3 expressing APCs by transfecting a plasmid encoding HLA-A3 into K562 cells ( Figure 4A-right panel) . As shown in Figure 4B , compared to control PBMC populations from normal adult volunteers (frequency <0.01%), using an E255K/A3-specific tetramer ( Figure 4C ). These data together support E255K-B as an endogenously processed and presented peptide epitope in the context of HLA-A3.
Mutated BCR-ABL peptide can elicit memory responses from imatinib-resistant patients
We next examined the potential of E255K-B for stimulating T cell responses in CML patients. In another example, Patient 3 developed a partial response to dasatinib for treatment of imatinibresistant disease, and subsequently underwent myeloablative allogeneic HSCT. PBMC collected before and after allo-HSCT were tested for reactivity to E255K-B. As shown in Figure   6 , reactivity was expanded in the setting of donor-derived engraftment following HSCT, concurrent with attainment of molecular remission. Increased reactivity by ELISpot ( Figure 6A BCR-ABL mutations, we identified peptides encoded by mutations that were predicted to bind to high frequency HLA class I alleles using well-validated prediction algorithms. The majority could be reliably validated through experimental binding studies. We used the example of a novel predicted HLA-A3+ restricted epitope derived from the common E255K mutation to demonstrate that mutated BCR-ABL peptides can stimulate CD8+ T cell responses that arise in association with effective therapeutic response. Our findings not only provide a rationale for developing tumor-specific immunotherapy for CML, but also support the feasibility of a broadly applicable approach for identifying neoplasm-specific neoantigens.
Our study predicted an unexpectedly large number of peptides encoded by common resistance mutations with potential to tightly bind multiple common HLA class I alleles. Our findings are consistent with recent studies that demonstrate that a bioinformatic approach can systematically identify a larger spectrum of immunogenic epitopes than by conventional T cell cloning-based tumor antigen discovery approaches (38) . We used both NetMHC and IEDB, as several comparative analyses have identified them as highly sensitive and specific across many common HLA class I alleles (28) . In agreement with Trost et al., we found that the intersecting results from muliple prediction tools more accurately predicted MHC class I peptide binding (39) . Of the three candidate peptides that we characterized in cellular assays, only one (E255K-B) was predicted as a high binder by both NetMHC and IEDB, and was determined to be a processed and presented epitope. Together, these findings suggest that a screening strategy using binding prediction criteria can efficiently generate a list of promising tumor neoepitopes. Furthermore, they highlight the increasing reliability of class I prediction servers for peptide binding against an expanded repertoire of HLA class I alleles beyond an examination restricted to HLA-A2 (conventionally, the focus of peptide prediction studies).
While BCR-ABL has long been considered a promising immunogen for tumor-specific immunotherapy, clinical studies overall have not been encouraging. This may be related in part to the previously unappreciated restricted spectrum of HLA haplotypes that have been confirmed to present BCR-ABL epitopes and thus have the potential to stimulate T cell responses (HLA-A3, -A11, and -B8 alleles) (40, 41) . Vaccine trials using wild-type BCR-ABL junctional peptides with or without heteroclitic peptides have not definitively demonstrated anti-tumor responses (42) (43) (44) . Furthermore, chronic persistence of BCR-ABL+ tumor cells appears to actively delete high-avidity CML-specific T cells over time (20) , and thus many barriers exist to mounting an effective cytolytic T cell response against an existing tumor antigen.
In contrast, our findings support the notion that peptides generated from a newly arising tumor mutation are not tolerogenic. We identified the development of CD8+ T cell responses in two examples of therapeutic response. In the first, BCR-ABL mutation-specific T cell responses developed following institution of a second generation TKI that effectively cytolysed tumor. In the case of Patient 3, E255K-B specific T cell responses were detected following allotransplant, a setting that enables the development of robust T cell immunity against tumorassociated antigens (47). In both the cases of Patient 2 and 3, we could show the limited potential for cross-reactivity to the associated wild-type peptide.
Our toolkit for promoting effective tumor immunity has expanded rapidly in recent years, and now include potent adjuvants, a variety of potentially efficacious delivery systems, and agents that can overcome checkpoint blockade (48). Thus, a priority is to identify antigens with truly tumor-specific expression so that a focused immune response can be generated without inciting potentially detrimental immune responses against normal tissue. While the specific application of our studies are limited to a small subset of TKI-treated CML patients who are both HLA-A3 positive and harbor the E255K mutation, our studies provide a rational basis for developing immunotherapy for any TKI-treated CML patient. Larger-scale studies to test immunogenicity 
of other imatinib-associated BCR-ABL mutation-related peptides would be anticipated to reveal a wider spectrum of immunogenic peptides that could elicit reactivity from a broader selection of HLA alleles. Hence, one could envision an immunotherapeutic approach that could be personalized based on the individual's HLA typing and BCR-ABL mutation genotype (49, 50).
Our approach is further generally applicable to other mutations related to resistance to other TKIs, that have been described to induce an alternate spectrum of BCR-ABL mutations (see Supplemental Figure 2 for analysis of potential peptide binders for common mutations related to dasatinib and nilotinib). BCR-ABL mutations "drive" CML relapse, and would be expected to be 
